These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33918040)

  • 1. Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant
    Wickremasinghe H; Yu HH; Azad MAK; Zhao J; Bergen PJ; Velkov T; Zhou QT; Zhu Y; Li J
    Antibiotics (Basel); 2021 Apr; 10(4):. PubMed ID: 33918040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Tait JR; Wallis SC; Peleg AY; Roberts JA; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.
    Schneider-Futschik EK; Paulin OKA; Hoyer D; Roberts KD; Ziogas J; Baker MA; Karas J; Li J; Velkov T
    ACS Infect Dis; 2018 May; 4(5):646-655. PubMed ID: 29566483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic Analysis of the Activity of a Novel Polymyxin against Staphylococcus aureus.
    Zhao J; Cheah SE; Roberts KD; Nation RL; Thompson PE; Velkov T; Du Z; Johnson MD; Li J
    mSphere; 2016; 1(4):. PubMed ID: 27471750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR
    Hussein M; Han ML; Zhu Y; Schneider-Futschik EK; Hu X; Zhou QT; Lin YW; Anderson D; Creek DJ; Hoyer D; Li J; Velkov T
    Comput Struct Biotechnol J; 2018; 16():587-599. PubMed ID: 30546859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.
    Lin YW; Yu HH; Zhao J; Han ML; Zhu Y; Akter J; Wickremasinghe H; Walpola H; Wirth V; Rao GG; Forrest A; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens.
    Tran TB; Wang J; Doi Y; Velkov T; Bergen PJ; Li J
    Front Microbiol; 2018; 9():721. PubMed ID: 29706941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments.
    Olsson A; Wistrand-Yuen P; Nielsen EI; Friberg LE; Sandegren L; Lagerbäck P; Tängdén T
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae.
    Aye SM; Galani I; Yu H; Wang J; Chen K; Wickremasinghe H; Karaiskos I; Bergen PJ; Zhao J; Velkov T; Giamarellou H; Lin YW; Tsuji BT; Li J
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32393492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
    Holger DJ; Lev KL; Kebriaei R; Morrisette T; Shah R; Alexander J; Lehman SM; Rybak MJ
    J Appl Microbiol; 2022 Sep; 133(3):1636-1649. PubMed ID: 35652690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.
    Qi L; Liang R; Duan J; Song S; Pan Y; Liu H; Zhu M; Li L
    J Antibiot (Tokyo); 2022 Oct; 75(10):567-575. PubMed ID: 35999263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.
    Abdul Rahim N; Cheah SE; Johnson MD; Yu H; Sidjabat HE; Boyce J; Butler MS; Cooper MA; Fu J; Paterson DL; Nation RL; Bergen PJ; Velkov T; Li J
    J Antimicrob Chemother; 2015 Sep; 70(9):2589-97. PubMed ID: 26023209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa.
    Hussein M; Han ML; Zhu Y; Zhou Q; Lin YW; Hancock REW; Hoyer D; Creek DJ; Li J; Velkov T
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.